Publications for Tove Sivik
Co-author map based on ISI articles 2007-
Publications mentioned in social media 1 times*
|Erik Hilborn, Tove Sivik, Tommy Fornander, Olle Stål, Bo Nordenskjöld and Agneta Jansson|
C-X-C ligand 10 and C-X-C receptor 3 status can predict tamoxifen treatment response in breast cancer patients
Breast Cancer Research and Treatment, 2014, 145(1), 73-82.
|Tove Sivik, Svante Vikingsson, Henrik Gréen and Agneta Jansson|
Expression Patterns of 17β-Hydroxysteroid Dehydrogenase 14 in Human Tissues
Hormone and Metabolic Research, 2012, 44(13), 949-956.
|Tove Sivik, Cecilia Gunnarsson, Tommy Fornander, Bo Nordenskjöld, Lambert Skoog, Olle Stål and Agneta Jansson|
17β-hydroxysteroid dehydrogenase type 14 is a predictive marker for tamoxifen response in oestrogen receptor positive breast cancer
PLoS ONE, 2012, 7(7), e40568.
Web of Science® Times Cited: 1
|Tove Sivik and Agneta Jansson|
Progesterone and levonorgestrel regulate expression of 17 beta HSD-enzymes in progesterone receptor positive breast cancer cell line T47D
Biochemical and Biophysical Research Communications - BBRC, 2012, 422(1), 109-113.
|Tove Sivik, Svante Vikingsson, Henrik Greén and Agneta Jansson|
A validated and rapid high-performance liquidchromatography method for the quantification ofconversion of radio-labelled sex steroids
Hormone Molecular Biology and Clinical Investigation, 2010, 3(1), 375-381.
|Agneta Jansson, Cecilia Gunnarsson, Maja Cohen, Tove Sivik and Olle Stål|
17β-hydroxysteroid dehydrogenase 14 affects estradiol levels in breast cancer cells and is a prognostic marker in estrogen receptor-positive breast cancer
Cancer Research, 2006, 66(23), 11471-11477.
Web of Science® Times Cited: 33
* Social media data based on publications from 2011 to present and with a DOI; data delivered by Altmetric.com.